DGAP-Adhoc: HumanOptics AG: Capital increase from authorized capital planned with exclusion of subscription rights; sustainable strengthening of equity base through conversion of liabilities

HumanOptics AG and its majority shareholder Medipart AG with seat in Unterägeri/Switzerland today agreed to carry out a capital increase from the authorized capital under exclusion of subscription rights in order to strengthen the equity capital on a sustained basis.

The share capital of the company, currently amounting to EUR 3,090,000.00, is to be increased by a nominal amount of EUR 50,000.00 to EUR 3,140,000.00 by issuing 50,000 new bearer shares with a pro rata amount of the share capital of EUR 1.00 per new share against contribution in kind. In consideration of the stock exchange price, the issue price shall be EUR 20.00 per new share, which shall thus be above the average closing price (arithmetic mean) of the HumanOptics share in XETRA trading on the Frankfurt Stock Exchange on the ten trading days in the period from 16 to 29 November 2018 in the amount of EUR 19.26. Medipart AG shall be admitted to subscribe the 50,000 new shares as a contribution in kind against contribution of a nominal amount of EUR 1,000,000.00 of its loan claims against HumanOptics AG.

The partial contribution of loan receivables will substantially reduce liabilities without affecting liquidity, reduce interest charges for the company and increase equity. The partial contribution of the loan receivables thus represents a significant contribution to the sustained strengthening of the company's equity base.

Contact: HumanOptics AG Investor Relations Spardorfer Str. 150 91054 Erlangen Telefon: +49 (0) 9131 50665-0 E-Mail: IR@humanoptics.com